<DOC>
	<DOCNO>NCT01257854</DOCNO>
	<brief_summary>Test correlation pharmacogenetic pharmacokinetic Busulfan IV child receive hematopoietic stem cell transplantation .</brief_summary>
	<brief_title>Polymorphisms Busulfan Pharmacokinetic Study</brief_title>
	<detailed_description>Most drug use treat cancer metabolize hepatic enzyme cytochrome P450 Glutathion-S-Transferase ( GST ) . These enzymatic pathway less active drug 's metabolism accord give polymorphism patient ( pharmacogenomics ) . The current hypothesis functional polymorphism gene , control important enzyme Busulfan metabolism , contribute observe interindividual variability PK drug . This variability hence predict resistance well toxicity drug patient cancer . The pharmacokinetic profile different drug , hepatic metabolism , dramatically modify polymorphism . Busulfan major drug use condition regimen hematopoietic stem cell transplantation , particularly child total body irradiation avoid . This drug narrow therapeutic index . At low systemic exposure target one , Busulfan insufficient activity hence increase risk transplant rejection leukemic relapse . At high systemic exposure , toxicity risk increase dramatically elevate incidence hepatic veno-occlusive disease ( VOD ) . Pharmacokinetic monitoring Busulfan allow optimal dosing . The recommended dos base weight , body surface area age . Nevertheless , majority patient still need adjustment dose administer first dose : result cumulative systemic exposure therapeutic . Busulfan metabolize principally GSTA1 , well GST enzyme like GSTM1 GSTP1 . These enzyme present liver well intestinal cell regulate digestive system young children.With study look polymorphism GST gene , look Busulfan IV pharmacokinetics finally look GST alpha enzyme activity see correlation clinical end point . This study also study correlation gene ( repair DNA gene , CYP etc.. ) could correlate Busulfan and/or cyclophosphamide . This study also allow DNA banking future study genetics . This multicentric study sponsor Swiss pediatric Oncology Group European Bone Marrow Transplantation study open 6 country ( Switzerland , Canada , Italy , Holland , Tscèque republic , ) . Pilot study first analyze St. Justine Hospital center later stage .</detailed_description>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Patients must ≤ 18 year age study entry protocol The patient must receive iv Busulfan part hematopoietic stem cell transplant condition regimen . Each participate center go PK cross validation All patient ( legal guardian ) must sign document informed consent approve Institutional Human Review Committee . Each center PK BU</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>busulfan</keyword>
	<keyword>pharmacogenetic</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>toxicity</keyword>
	<keyword>survival</keyword>
</DOC>